title: Effect of spirogermanium and radiation therapy on the 9L rat brain tumor model.
abstract: Spirogermanium (SPG) was investigated in the 9L rat brain tumor model in vivo and in vitro. Used at a single ip dose of 50 or 60 mg/kg or at 5 daily doses of 10 mg/kg, SPG was ineffective in prolonging survival of rats burdened with the intracerebrally implanted tumor, i.e., the median survival time (MST) was the same as that for the controls. Only a schedule of 3 X 20 mg SPG/kg every other day improved the MST compared with controls. Single-dose (20-Gy) radiation therapy (RT, cesium-137 whole-head irradiation) did prolong survival. However, when single-dose SPG was combined with RT (1 hr or 1 day before, or 1 hr after RT), the survival response was worse than after RT alone. When the daily SPG was combined with daily RT (5 doses of 6 Gy), survival was no better than after daily RT alone. In vitro, SPG produces a concentration-dependent, exponential decrease in cell survival as measured by colony formation assay. When combined with radiation, there is an additive effect on cell lethality. Aside from the possibility that SPG does not penetrate the rat brain tumor itself, we have no explanation why SPG shows some activity against human brain tumors and is cytotoxic against 9L cells in vitro, yet is both ineffective by itself and fails to potentiate RT in the 9L rat brain tumor model.
authors.affiliation: Department of Radiation Oncology, University of Kansas Medical Center, Kansas City 66103.
authors.forename: B F
authors.initials: BF
authors.lastname: Kimler
authors.forename: D F
authors.initials: DF
authors.lastname: Martin
authors.forename: R G
authors.initials: RG
authors.lastname: Evans
authors.forename: R A
authors.initials: RA
authors.lastname: Morantz
authors.forename: T S
authors.initials: TS
authors.lastname: Vats
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D051381:Rats; D011916:Rats, Inbred F344; D013141:Spiro Compounds / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; C026818:spirogermanium